|
KMID : 0918520180180020062
|
|
Journal of the Korean Society of Inherited Metabolic Disease
2018 Volume.18 No. 2 p.62 ~ p.67
|
|
|
A Case of Hunter Syndrome Diagnosed at 7 Months of Age by Exome Sequencing
|
|
Song A-Ri
Lee Jin-Sung
Im Min-Ji
Park Hyung-Doo
Cho Sung-Yoon
Jin Dong-Kyu
|
|
|
Abstract
|
|
|
Hunter syndrome, also known as mucopolysaccharidosis Type II (MPS II), is one of the lysosomal storage diseases caused by a lack of the enzyme iduronate 2-sulfatase (I2S). Lack of the I2S enzyme activity leads to accumulation of the glycosaminoglycans (GAG), causing dysfunction of multiple organs and systems. MPS II is an X-linked recessive disease due to mutation of IDS gene located on long arm of the X chromosome (Xq28). To date, more than 350 mutations of IDS gene have been identified in Hunter syndrome. Phenotypes of MPS II are classified as either severe or attenuated depending on the degree of cognitive impairment. Because the phenotype of MPS II is related to the type of mutation,
identifying mutations is useful in predicting prognosis. We recently had a case of MPS II diagnosed by exome sequencing in a 7 month old boy with infantile spasm uncontrolled by AED. He was diagnosed with hearing loss at 2 months of age, and he took vigabatrin and prednisolone to control infantile spasms diagnosed at 3 months of age. At 6 months of age, whole exome sequencing was performed to evaluate the infantile spasm and hearing loss in this patient, and the mutation c.851C>T (p.Pro284Leu) inherited from hemizygous mother was revealed. The results of urine Cetylpyridinium Chloride (CPC) precipitation test, which were negative until 8 months of age, were positive from 9 months of age. We report a case of MPS II diagnosed by exome sequencing and treated through enzyme replacement therapy from 9 months after birth.
|
|
|
KEYWORD
|
|
|
Mucopolysaccharidosis II, Hunter syndrome, Whole exome sequencing, Iduronate surfatase
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|